Glucagon-like peptide-1 physiology and pharmacology
A variety of GLP-1RAs agents are currently available, including exenatide, liraglutide, dulaglutide, albiglutide, lixisenatide, semaglutide, and the dual GLP-1/GIP receptor agonist, tirzepatide
Australian Institute of Health and Welfare (AIHW)
It should not be administered at home without a trained professional
About the Study Study Type : Prospective, single-arm study evaluating the off-label use of GLP-1 RAs Duration : 24 months Participants : 110 adults with upper or lower extremity lymphedema (ISL Stages II and III) Primary Objective : Assess improvements in quality of life using the Lymphedema Life Impact Scale (LLIS) Secondary Objectives : Measure changes in limb volume, bioimpedance, BMI, compression use, and incidence of cellulitis Participants will receive GLP-1 RA treatment for six months, with the medication prescribed and managed by their primary healthcare provider